What the FDA labels say about taking them together
Midazolam and verapamil
Midazolam's FDA label of January 1, 2024 names verapamil in its drug interactions section; the verapamil labels PlainMeds reads (4) do not name midazolam. The midazolam label: “Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam.”
Check it at the source: the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC); the verapamil FDA label on DailyMed (effective April 6, 2026, Zydus Pharmaceuticals (USA) Inc.).
What does the midazolam label say about verapamil?
Midazolam label, drug interactionsOther Drug Interactions Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the P450-3A4 enzyme system such as cimetidine (not ranitidine), erythromycin, diltiazem, verapamil, ketoconazole and itraconazole.
N/A label (Rafa Laboratories, Ltd., February 18, 2026), drug interactionsCytochrome P450-3A4 Inhibitors Caution is advised when Midazolam Injection is administered concomitantly with drugs that are known to inhibit the P450-3A4 enzyme system (e.g., cimetidine, erythromycin, diltiazem, verapamil, ketoconazole, and itraconazole).
Nayzilam label (UCB, Inc., January 19, 2023), drug interactions7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamil Strong CYP3A4 inhibitors: ketoconazole, itraconazole …
Midazolam In Sodium Chloride label (WG Critical Care, LLC., July 31, 2025), drug interactionsConcomitant administration with drugs that are known to inhibit the P450-3A4 enzyme system, such as cimetidine (not ranitidine), erythromycin, diltiazem, verapamil, ketoconazole and itraconazole, may result in prolonged sedation due to a decrease in plasma clearance of midazolam.
Source: FDA drug label (N/A, NDA216359), Rafa Laboratories, Ltd., effective February 18, 2026 (SPL set d7362b4d-68a3-99a0-e053-2995a90a4f60), via openFDA
Source: FDA drug label (Nayzilam, NDA211321), UCB, Inc., effective January 19, 2023 (SPL set 2b29422e-54d5-4a49-8522-e9cf752368c3), via openFDA
Source: FDA drug label (Midazolam In Sodium Chloride, NDA211844), WG Critical Care, LLC., effective July 31, 2025 (SPL set f051776f-94c5-4e34-80ed-f45b9c36881e), via openFDA
Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed
What does the verapamil label say about midazolam?
Verapamil's label (effective April 6, 2026) and its 3 other brand-application labels do not name midazolam in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Verapamil hydrochloride), Zydus Pharmaceuticals (USA) Inc., effective April 6, 2026 (SPL set e19ab8d8-dae5-489d-9805-7e7407bea06d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Midazolam | Verapamil | |
|---|---|---|
| Labeled for | n/a | High blood pressure, Atrial fibrillation, Angina |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.233 per mL 2 mg/2 mL vial | $0.191 per tablet 180 mg tablet |
| Shortage now | In shortage | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once